|
| 1 |
|
Conditions listed in this trial |
|
|
Kidney Cancer |
|
|
Sarcoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Carcinoma, Renal Cell |
|
|
Kidney Neoplasms |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
|
Neuroectodermal Tumors, Primitive, Peripheral |
|
|
Sarcoma, Ewing's |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adenocarcinoma |
|
|
Carcinoma |
|
|
Kidney Diseases |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Bone Tissue |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Connective Tissue |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
|
Osteosarcoma |
|
|
Urogenital Neoplasms |
|
|
Urologic Diseases |
|
|
Urologic Neoplasms |
|
| 4 |
|
Interventions listed in this trial |
|
|
cyclophosphamide |
|
|
doxorubicin hydrochloride |
|
|
etoposide |
|
|
ifosfamide |
|
|
vincristine sulfate |
|
|
conventional surgery |
|
|
radiation therapy |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Doxorubicin |
|
|
Isophosphamide mustard |
|
|
Vincristine |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Antibiotics, Antineoplastic |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Antirheumatic Agents |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Memorial Sloan-Kettering Cancer Center |
